About: John M. Kane

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: John M. Kane Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

International leader in the field of schizophrenia research

Attributes	Values
rdf:type	Item
owl:sameAs	John M. Kane
description	forskare (sv) 연구원 (ko) 研究者 (ja) araştırmacı (tr) वैज्ञानिक (hi) изилдөөчү (ky) 研究者 (zh) հետազոտող (hy) psychiater (nl) International leader in the field of schizophrenia research (en)
rdfs:label	John M. Kane (en) John M. Kane (nl) John M. Kane (sq) John M. Kane (ast)
skos:prefLabel	John M. Kane (en) John M. Kane (nl) John M. Kane (sq) John M. Kane (ast)
name	John M. Kane (en) John M. Kane (nl) John M. Kane (sq) John M. Kane (ast)
given name	wds:Q52274733-2B8842DB-648F-4E33-8D98-B3D0E4EC69A2
given name	John
instance of	wds:Q52274733-C79B24B6-498A-4E69-B46F-61D46B184E5C
instance of	Homo sapiens
award received	wds:Q52274733-3E8ABEE7-085D-4478-86FF-F330ED9A7C68
award received	Fellow of the New York Academy of Medicine
Google Knowledge Graph ID	wds:Q52274733-9CDC8E4D-FB5A-4C1B-B524-7DC9BB7C6F3C
Google Knowledge Graph ID	http://g.co/kg/g/11hdj3z3ll
Google Knowledge Graph ID	/g/11hdj3z3ll
skos:altLabel	John Kane (en) John M Kane (en) John M Kane (nl) John M Kane (es) John M Kane (ast) John M. Kane, MD (en) Kane JM (en)
occupation	wds:Q52274733-3682abf0-6c2d-4a38-8fb3-48792a8a2a9d wds:Q52274733-7139EC40-6E36-4712-A0BF-7EE5CC2D6E1B
employer	wds:Q52274733-CFEE1324-5311-4374-B8F3-49A4868D5C64
sex or gender	wds:Q52274733-7627B5F4-8B37-4A9C-9257-058B4B139E5A
ISNI	wds:Q52274733-F4E22789-5131-4B48-94D5-93ACE9B45959
VIAF ID	wds:Q52274733-F11FC214-5D4E-47B9-AC13-EB045F3869B9
GND ID	wds:Q52274733-e27cc61d-304d-4762-8bd1-f501eab7d6bd
IdRef ID	wds:Q52274733-A0EE0584-3395-434D-A12C-F1C47253999C
member of	wds:Q52274733-AB66988F-1FD5-459E-B4C5-61D98D8BDA33
academic degree	wds:Q52274733-A8177318-B2C2-4406-9EFA-AE86FBBC6C4F
date of birth	wds:Q52274733-8591B255-0141-4FD9-89B9-20D10A8F2CD6
family name	wds:Q52274733-E9D6A394-04DC-44C4-A6AE-9290D06076CA
National Library of Spain ID	wds:Q52274733-C32A2552-675E-4C29-BCDF-50F7284F94A2
VIAF ID	http://viaf.org/viaf/109751475
GND ID	https://d-nb.info/gnd/11375597X
IdRef ID	http://www.idref.fr/110147200/id
National Library of Spain ID	http://datos.bne.es/resource/XX4768837
occupation	psychiatrist researcher
employer	Zucker Hillside Hospital
sex or gender	male
ISNI	0000000107879570
VIAF ID	109751475
GND ID	11375597X
IdRef ID	110147200
member of	New York Academy of Medicine
academic degree	Doctor of Medicine
date of birth	1945-01-01 00:00:00Z (xsd:dateTime)
family name	Kane
National Library of Spain ID	XX4768837
ORCID iD	wds:Q52274733-65E7CC10-7C1C-4481-965E-D26239BD2066
ORCID iD	https://orcid.org/0000-0002-2628-9442
ORCID iD	0000-0002-2628-9442
is owl:sameAs of	John M. Kane
is about of	John M. Kane https://www.wikidata.org/wiki/Special:EntityData/Q52274733 John M. Kane
is author of	When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature Predictors of remission, schizophrenia, and bipolar disorder in adolescents with brief psychotic disorder or psychotic disorder not otherwise specified considered at very high risk for schizophrenia Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study DISC1 and neurocognitive function in schizophrenia. The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics. Pharmacologic treatment of schizophrenia Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia Past and present progress in the pharmacologic treatment of schizophrenia The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. Genomics and the future of pharmacotherapy in psychiatry Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics Neurocognitive profile in adolescents with early-onset schizophrenia: clinical correlates. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Lessons learned in the conduct of a global, large simple trial of treatments indicated for schizophrenia Genetic variation in DTNBP1 influences general cognitive ability Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies The Mount Sinai conference on the pharmacotherapy of schizophrenia Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software